BridgeBio Pharma BBIO Restructuring, Settlement and Impairment Provisions
Restructuring, Settlement and Impairment Provisions at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RestructuringSettlementAndImpairmentProvisions.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's restructuring, settlement and impairment provisions.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's restructuring, settlement and impairment provisions?
- BridgeBio Pharma (BBIO) reported restructuring, settlement and impairment provisions of $0 in Q1 2026.
- How has BridgeBio Pharma's restructuring, settlement and impairment provisions changed year-over-year?
- BridgeBio Pharma's restructuring, settlement and impairment provisions decreased by 100.0% year-over-year, from $570K to $0.
- What is the long-term trend for BridgeBio Pharma's restructuring, settlement and impairment provisions?
- Over 2 years (2023 to 2025), BridgeBio Pharma's restructuring, settlement and impairment provisions has grown at a 64.1% compound annual growth rate (CAGR), from $7.93M to $21.35M.
- What does restructuring, settlement and impairment provisions mean?
- One-time costs related to reorganizing the company, legal disputes, or writing down the value of assets.
- How do you interpret restructuring, settlement and impairment provisions?
- Frequent or large charges may signal poor capital allocation or operational instability, while zero or low values indicate a stable business environment.
- How does restructuring, settlement and impairment provisions compare across companies?
- Highly idiosyncratic; peers will only show these during periods of significant corporate change or litigation.